LitAlert ~~ GeneLit.com

    • S100A9-CXCL12 activation in BRCA1-mutant breast cancer promotes an immunosuppressive microenvironment associated with resistance to immunotherapy.
    • Li J, Shu X, Xu J, Su SM, Chan UI, Mo L, Liu J, Zhang X, Adhav R, Chen Q, Wang Y, An T, Zhang X, Lyu X, Li X, Lei JH, Miao K, Sun H, Xing F, Zhang A, Deng C, Xu X.
    • Nat Commun. 2022 Mar 18;13(1):1481. doi: 10.1038/s41467-022-29151-5.

    • Influence of cellular models and individual factor in the biological response to chest CT scan exams.
    • Devic C, Bodgi L, Sonzogni L, Pilleul F, Ribot H, Charry C, Le Moigne F, Paul D, Carbillet F, Munier M, Foray N.
    • Eur Radiol Exp. 2022 Mar 17;6(1):14. doi: 10.1186/s41747-022-00266-0.

    • Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer.
    • Shim JI, Ryu JY, Jeong SY, Cho YJChoi JJ, Hwang JR, JY, Sa JK, Lee JW.
    • Gynecol Oncol. 2022 Mar 16:S0090-8258(22)00176-7. doi: 10.1016/j.ygyno.2022.03.005. Epub ahead of print.

    • BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling.
    • Bradbury M, Borràs E, Castellví J, Méndez O, Sánchez-Iglesias JL, Pérez-Benavente A, Gil-Moreno A, Sabidó E, Santamaria A.
    • Sci Rep. 2022 Mar 15;12(1):4445. doi: 10.1038/s41598-022-08461-0.